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α-Galactosylceramide (α-GalCer or KRN7000; 1) is well known as the archetypical glycolipid 
nowadays serving as a lead structure for new analogues, which could act as vaccine 
adjuvants or as therapeutically useful immunomodulators. α-GalCer is presented by antigen-
presenting cells (APCs) through interaction with CD1d, a membrane-bound glycoprotein. As 
the two lipophilic chains of α-GalCer act as anchoring points in CD1d via hydrophobic 
interactions, the polar sugar part is presented at the surface of CD1d to be recognized by the 
T-cell receptor (TCR) of invariant natural killer T-cells (iNKT). The formation of this ternary 
CD1dglycolipid-TCR complex triggers iNKT cells to release both Th1- and Th2-cytokines, 
small signaling proteins that are responsible for several biological effects in the immune 
system. 
 
The main hypothesis used to explain the differences in cytokine response provoked by 
different α-GalCer analogues encompasses the stability of the glycolipid-CD1d complex. It is 
assumed that a stronger glycolipid-CD1d interaction will lead to a proportionally higher 
release of Th1-cytokines, thereby establishing pro-inflammatory effects. To test this 
hypothesis, a set of five α-GalCer analogues (2a-e), each bearing a terminal phenyl moiety in 
the phytosphingosine chain, was successfully synthesized. The incorporation of an extra 
aromatic ring aims at enhanced hydrophobic Van der Waals interactions within the binding 
pocket of CD1d. The syntheses were accomplished relying on chiral pool chemistry, with a 
Wittig-olefination and an α-selective Schmidt glycosylation as the key bond-forming steps. 
Preliminary biological results of the analogues will be presented. 
 
 
